Uncertainty in the U.S. Market Environment from Tariffs and Drug-Price Reduction Policies
First written in FY2025. 2 of 3 entries say "Restated". Latest entry: 2026-08-05.
The whole theme swung hardest in 2020: 25 of 58 companies on the "Worse" side.
47 other companies' latest entry also says "Restated".
- 2026-08-05RestatedEarnings
「In the United States, the impact of government policy on the pharmaceutical industry remains uncertain, while in China, centralized procurement systems operated by the government and provinces are expanding, making market trends difficult to predict.」
The company continued to state that U.S. government policy and China's centralized procurement system make market forecasts difficult. - FY2026-H1RestatedAnnual report
「In the U.S., the impact of government policies on the pharmaceutical industry remains uncertain. In China, centralized procurement systems led by the government and provinces are also expanding, making market trends difficult to predict.」
The company continued to describe the impact of U.S. government policies on the pharmaceutical industry as uncertain. It also stated that market forecasts in China are difficult due to the expansion of centralized procurement systems led by the government and provinces. - FY2025First statedAnnual report
「The impact of tariffs and drug price-cut policies under the Trump administration on the U.S. market, one of the company's key overseas markets, remains uncertain. The company will closely monitor developments while coordinating with its commercial partners.」
The uncertain impact of government tariffs and drug price-cut policies on the U.S. market was described as a new external risk.